Skip to content

US · CLDX · BIOTECHNOLOGY

Celldex Therapeutics, Inc. (CLDX) intrinsic value and stock valuation

$27.42as of 2026-11-21 · Mkt cap 2.73B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Celldex Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CLDX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from CLDX’s statements →

Celldex Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Hampton, NJ 08827 celldex.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.5M-27.4% 5y CAGRd
20112025
Net income
-$-258.8M
20112025
Free cash flow
-$-213.66M
20112025
Total equity
$527.2M+20.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.5M$7.02M$6.88M$2.36M$4.65M
Operating income-$-287.4M-$-195.08M-$-154.54M-$-115.23M-$-71.24M
Net income-$-258.8M-$-157.86M-$-141.43M-$-112.33M-$-70.51M
EPSd-$-3.89M-$-2.45M-$-2.92M-$-2.4M-$-1.64M
Operating cash flow-$-210.94M-$-157.78M-$-107.29M-$-103.73M-$-60.91M
Capital expenditure-$-2.71M-$-1.92M-$-1.82M-$-1.83M-$-1.25M
Free cash flow-$-213.66M-$-159.7M-$-109.11M-$-105.56M-$-62.16M
Total assets$583M$792.3M$465.6M$352.7M$444.7M
Total debt$2.34M$3.81M$2.54M$4.03M$3.04M
Net debt-$-26.54M-$-24.54M-$-32.27M-$-25.4M-$-36.1M
Total equity$527.2M$747M$429.2M$326.2M$419.5M
Cash and short-term investments$518.6M$725.3M$421.7M$305M$408.3M
Income statement
20252024202320222021
Revenue$1.5M$7.02M$6.88M$2.36M$4.65M
Cost of revenue$0.00$163.6M$118M$82.3M$53.3M
Gross profit$1.5M-$-156.53M-$-111.13M-$-79.9M-$-48.66M
Research and development expenses$245.1M$163.6M$118M$82.3M$56.8M
Selling, general and administrative expenses$43.8M$38.6M$30.9M$27.2M$20.5M
Other expenses$0.00-$-163.55M-$-105.51M-$-74.12M-$-54.72M
Operating expenses$288.9M$38.6M$43.4M$35.3M$22.6M
Cost and expenses$288.9M$202.1M$161.4M$117.6M$75.9M
Interest income$28.6M$37.2M$13.1M$2.91M$510K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.38M$3.18M$3.01M$2.9M$3.07M
Ebitda-$-255.42M-$-154.69M-$-139.03M-$-104.2M-$-66.08M
Operating income-$-287.4M-$-195.08M-$-154.54M-$-115.23M-$-71.24M
Total other income/expenses, net$28.6M$37.2M$13.1M$2.91M$510K
Income before tax-$-258.8M-$-157.86M-$-141.43M-$-112.33M-$-70.74M
Income tax expense$0.00$0.00$0.00$0.00-$-230K
Net income-$-258.8M-$-157.86M-$-141.43M-$-112.33M-$-70.51M
Weighted average shares outstanding$66.5M$64.4M$48.5M$46.9M$42.9M
Weighted average diluted shares outstanding$66.5M$64.4M$48.5M$46.9M$42.9M
Balance sheet
20252024202320222021
Cash and short-term investments$518.6M$725.3M$421.7M$305M$408.3M
Net receivables$2.02M$700K$4.53M$350K$170K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$534.7M$747.2M$431.7M$317.7M$410.8M
Property, plant and equipment, net$7.77M$8.24M$6.64M$7.75M$6.52M
Goodwill and intangible assets$27.2M$27.2M$27.2M$27.2M$27.2M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$48.3M$45.2M$33.9M$35M$33.8M
Total assets$583M$792.3M$465.6M$352.7M$444.7M
Accounts payable$1.18M$3.27M$3.49M$3.34M$1.23M
Short-term debt$1.55M$1.45M$1.61M$1.45M$1.75M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$51M$39.5M$31.1M$18.6M$16.5M
Long-term debt$780K$2.36M$930K$2.59M$1.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.83M$5.83M$5.33M$7.92M$8.65M
Capital lease obligations$2.34M$3.81M$2.54M$4.03M$3.04M
Total liabilities$55.8M$45.3M$36.5M$26.5M$25.2M
Common stock$70K$70K$60K$50K$50K
Retained earnings-$-1.81B-$-1.56B-$-1.4B-$-1.26B-$-1.14B
Accumulated other comprehensive income (loss)$3.63M$3.31M$3.31M$1.26M$1.89M
Total equity$527.2M$747M$429.2M$326.2M$419.5M
Total investments$489.7M$696.9M$386.9M$275.5M$369.1M
Total debt$2.34M$3.81M$2.54M$4.03M$3.04M
Net debt-$-26.54M-$-24.54M-$-32.27M-$-25.4M-$-36.1M
Cash flow statement
20252024202320222021
Net income-$-258.76M-$-157.86M-$-141.43M-$-112.33M-$-70.51M
Depreciation and amortization-$-2.48M$3.18M$3.01M$1.4M$3.07M
Stock-based compensation$36.2M$34.2M$23.9M$0.00$8.95M
Change in working capital$14.1M-$-21.6M$13.5M-$-3.9M-$-1.05M
Accounts receivable-$-1.31M$1.93M-$-2.28M-$-170K$1.57M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$11M$11.6M$9.38M$3.12M$3.65M
Net cash provided by operating activities-$-210.94M-$-157.78M-$-107.29M-$-103.73M-$-60.91M
Investments in property, plant and equipment-$-2.71M-$-1.92M-$-1.82M-$-1.83M-$-1.25M
Acquisitions, net$0.00$0.00$0.00$70K$30K
Net cash used for investing activities$209.1M-$-290.13M-$-105.78M$89.9M-$-216.16M
Common stock issued$2.39M$432.3M$216.2M$4.08M$269.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.39M$441.5M$218.5M$4.08M$272.4M
Net change in cash$520K-$-6.46M$5.38M-$-9.71M-$-4.69M
Cash at end of period$28.9M$28.4M$34.8M$29.4M$39.1M
Operating cash flow-$-210.94M-$-157.78M-$-107.29M-$-103.73M-$-60.91M
Capital expenditure-$-2.71M-$-1.92M-$-1.82M-$-1.83M-$-1.25M
Free cash flow-$-213.66M-$-159.7M-$-109.11M-$-105.56M-$-62.16M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Celldex Therapeutics, Inc.

        Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

        CEO
        Anthony S. Marucci
        Employees
        198
        Beta
        0.90

        Explore

        Frequently asked questions

        What is the intrinsic value of Celldex Therapeutics, Inc. (CLDX)?

        Celldex Therapeutics, Inc. (CLDX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CLDX undervalued?

        CLDX trades at a price of $27.42 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.